Analysis of circulating tumor cells(CTCs) and clinical significance of CTCs; human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trial

Analysis of circulating tumor cells(CTCs) and clinical significance of CTCs; human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trial - Analysis of circulating tumor cells in the clinical study of ANP administration for lung cancer surgery (JANP study) (Subanalysis of JANP study)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024302

Enrollment

500

Registered

2016-10-19

Start date

2015-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

A: Lung cancer surgery with hANP treatment [Patients in the hANP group receive human ANP (0.025 microgram/kg/min for 3 days), which is started more than two hours before surgery] B: Surgery alone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Preoperative criteria 1. Non-small cell lung cancer is suspected. 2. Thin-section CT fulfills the proportion of maximum diameter of the tumor itself to consolidation is more than 0.25. 3. It's possible to perfom the complete resection including mediastinal lymph node dissection. 4. Patient without simultaneous or metachronous (within the past 5 years) double cancers. 5. Aged more than 20 years 6. Performance status of 0-2. 7. Sufficient organ functions. 8. All patients gave written informed consent

Exclusion criteria

Exclusion criteria: 1. Thin-section CT fulfills the proportion of maximum diameter of the tumor itself to consolidation is less than 0.25. 2. Patient with active the other concurrent malignant diseases. 3. Women during pregnancy or breast-feeding. 4. Psychosis. 5. Systemic steroids or immunosuppressive agents medication. 6. Uncontrollable infectious disease, autoimmune disease, or the other severe comorbidities. 7. History of right ventricular infarction. 8. Severe hypotension 9. Other conditions judged ineligible by physician

Design outcomes

Primary

Measure	Time frame
The presence of circulating tumor cells (CTCs) their morphological characteristics and clinicopathological character, overall survival and disease-free survival,	—

Countries

Japan

Contacts

Public ContactSoichiro Funaki

Osaka University Graduate School of Medicine General Thoracic Surgery

funaki@thoracic.med.osaka-u.ac.jp06-6879-3152

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026